Drug Profile
Research programme: pro-anti-inflammatory monoclonal antibodies - ProtAb
Alternative Names: Proximab; ProzumabLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ProtAb
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 10 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Israel (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Israel (Parenteral)